Geode Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-470,631
| Closed | -$45.6M | – | 4257 |
|
|
2019
Q3 | $45.6M | Buy |
470,631
+24,262
| +5% | +$2.43M | 0.01% | 939 |
|
|
2019
Q2 | $45.7M | Buy |
446,369
+48,960
| +12% | +$5.28M | 0.01% | 921 |
|
|
2019
Q1 | $45.3M | Buy |
397,409
+27,409
| +7% | +$2.01M | 0.01% | 891 |
|
|
2018
Q4 | $14.5M | Buy |
370,000
+33,414
| +10% | +$1.45M | ﹤0.01% | 1507 |
|
|
2018
Q3 | $18.4M | Buy |
336,586
+12,444
| +4% | +$851K | 0.01% | 1473 |
|
|
2018
Q2 | $26.8M | Buy |
324,142
+30,076
| +10% | +$2.32M | 0.01% | 1142 |
|
|
2018
Q1 | $19.6M | Buy |
294,066
+17,747
| +6% | +$1.02M | 0.01% | 1280 |
|
|
2017
Q4 | $14.2M | Buy |
276,319
+4,304
| +2% | +$309K | ﹤0.01% | 1500 |
|
|
2017
Q3 | $24.3M | Buy |
272,015
+72,974
| +37% | +$5.54M | 0.01% | 1097 |
|
|
2017
Q2 | $11.9M | Buy |
199,041
+21,887
| +12% | +$1.22M | ﹤0.01% | 1544 |
|
|
2017
Q1 | $9.45M | Buy |
177,154
+8,284
| +5% | +$492K | ﹤0.01% | 1654 |
|
|
2016
Q4 | $8.43M | Buy |
168,870
+5,883
| +4% | +$315K | ﹤0.01% | 1699 |
|
|
2016
Q3 | $9.79M | Buy |
162,987
+12,413
| +8% | +$716K | ﹤0.01% | 1512 |
|
|
2016
Q2 | $7.7M | Buy |
150,574
+50,009
| +50% | +$2.14M | ﹤0.01% | 1628 |
|
|
2016
Q1 | $2.97M | Buy |
100,565
+8,289
| +9% | +$261K | ﹤0.01% | 2193 |
|
|
2015
Q4 | $4.18M | Buy |
92,276
+13,868
| +18% | +$727K | ﹤0.01% | 1991 |
|
|
2015
Q3 | $3.27M | Buy |
78,408
+20,023
| +34% | +$1.04M | ﹤0.01% | 2121 |
|
|
2015
Q2 | $3.52M | Buy |
+58,385
| New | +$3.86M | ﹤0.01% | 2141 |
|
Geode Capital Management's ONCE Position: Q4 2019 in Review
Geode Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 470,631 shares — an estimated $45.6M sold.
Geode Capital Management first reported a position in ONCE in Q2 2015 and held it in 18 quarters. The position peaked at $45.7M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Geode Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Geode Capital Management sold 470,631 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $45.6M.
- Geode Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 18 quarters.
- Geode Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $45.7M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Geode Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.